Literature DB >> 21109969

Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.

Rongjiao Guo1, Qiuhua Wu, Fenghua Liu, Yifeng Wang.   

Abstract

Cancer stem cells (CSCs) form a very rare population within tumors and possess the ability to proliferate and self-renew indefinitely. The cluster of differentiation (CD) 133+ ovarian CSCs (OCSCs) have been identified recently and their clinical implications are about to be clarified. In this context, we use the CD133 antigen as a marker of OCSCs in OVCAR3 cells and show that microRNAs (miRNAs) are aberrantly expressed in this subpopulation. The OCSCs in the OVCAR3 cell line were identified by the monoclonal mouse anti-CD133-1 antibody (clone CD133). Microarray and real-time reverse transcription-polymerase chain reaction (RT-PCR) analyses were used to identify miRNAs with altered expression in CD133+ cells. The expression levels of dysregulated miRNAs, namely, miR-204, miR-206, miR-223, miR-9, miR-100, and miR-200c, were examined using TaqMan PCR. The RNA and protein levels of stem cell-specific genes were examined by real-time RT-PCR and western blot analyses. Our results of microarray and real-time RT-PCR analyses revealed distinct miRNA expression profiles between CD133+ and CD133- OVCAR3 cells. The expression of stem cell-specific genes, namely, Oct3/4, Sox2, and Nanog, was higher in CD133+ cells than in CD133- cells while that of FoxD3, was lower in CD133+ cells than in CD133- cells. In conclusion, our data indicate that CD133 expression defines a tumor-initiating subpopulation of cells in the OVCAR3 cell line. The overall miRNA expression profile of CD133+ OVCAR3 cells was clearly distinct from that of CD133- OVCAR3 cells, indicating that miRNAs are involved in the development of this neoplasia and may serve as pertinent chemotherapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21109969

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma.

Authors:  Zhenyu Wu; Liang Wang; Gang Li; Hui Liu; Feiyan Fan; Zhaobo Li; Yunqing Li; Guodong Gao
Journal:  Mol Cell Biochem       Date:  2013-12       Impact factor: 3.396

2.  CD133 expression associated with poor prognosis in ovarian cancer.

Authors:  Jing Zhang; Xiaoqing Guo; Doo Young Chang; Daniel G Rosen; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-11-11       Impact factor: 7.842

3.  Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer.

Authors:  Jimmy Belotte; Nicole M Fletcher; Mitchell Alexis; Robert T Morris; Adnan R Munkarah; Michael P Diamond; Ghassan M Saed
Journal:  Reprod Sci       Date:  2014-07-18       Impact factor: 3.060

4.  microRNA expression is able to predict response to chemoradiotherapy in rectal cancer.

Authors:  Masanori Hotchi; Mitsuo Shimada; Nobuhiro Kurita; Takashi Iwata; Hirohiko Sato; Shinya Morimoto; Kozo Yoshikawa; Jun Higashijima; Tomohiko Miyatani
Journal:  Mol Clin Oncol       Date:  2012-08-09

5.  TRA-1-60+, SSEA-4+, Oct4A+, Nanog+ Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Ovaries.

Authors:  Marek Malecki; Mark Anderson; Michael Beauchaine; Songwon Seo; Xenia Tombokan; Raf Malecki
Journal:  J Stem Cell Res Ther       Date:  2012-11-18

6.  MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line.

Authors:  Eun Ji Nam; Maria Lee; Ga Won Yim; Jae Hoon Kim; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  BMC Med Genomics       Date:  2012-05-29       Impact factor: 3.063

7.  Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells.

Authors:  Lei Tan; Xin Sui; Hongkui Deng; Mingxiao Ding
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

8.  In vitro enrichment of ovarian cancer tumor-initiating cells.

Authors:  Carrie D House; Lidia Hernandez; Christina M Annunziata
Journal:  J Vis Exp       Date:  2015-02-18       Impact factor: 1.355

Review 9.  MicroRNA-206: a promising theranostic marker.

Authors:  Jan Novák; Peter Kružliak; Julie Bienertová-Vašků; Ondřej Slabý; Miroslav Novák
Journal:  Theranostics       Date:  2014-01-02       Impact factor: 11.556

10.  MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro.

Authors:  Wei-Min Chung; Wei-Chun Chang; Lumin Chen; Ying-Yi Chang; Chih-Rong Shyr; Yao-Ching Hung; Wen-Lung Ma
Journal:  Stem Cell Res Ther       Date:  2013-07-26       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.